Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
138 hedge funds and large institutions have $1.37B invested in Sage Therapeutics in 2015 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 53 increasing their positions, 42 reducing their positions, and 23 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 42
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
19% more capital invested
Capital invested by funds: $1.15B → $1.37B (+$216M)
17% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 23
2% more funds holding
Funds holding: 135 → 138 (+3)
25% less call options, than puts
Call options by funds: $5.22M | Put options by funds: $6.95M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$41.4M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$35.1M |
| 3 |
Millennium Management
New York
|
+$25.7M |
| 4 |
Jennison Associates
New York
|
+$12.6M |
| 5 |
Bank of New York Mellon
New York
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$17.3M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$15.1M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$9.14M |
| 4 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
-$6.74M |
| 5 |
O
OrbiMed
New York
|
-$6.35M |
SAGE Hedge Fund Activity: Q4 2015 in Review
138 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q4 2015, worth a combined $1.37B — up 19% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new SAGE positions and 23 closed out — a net gain of 4 holders — while 53 added to existing stakes and 42 trimmed.
The largest buyer was Lord, Abbett & Co, adding an estimated $41.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $17.3M.
- 138 institutional investors held Sage Therapeutics (SAGE) as of Q4 2015, up from 135 in Q3 2015.
- Funds reported $1.37B of Sage Therapeutics stock for Q4 2015, up 19% quarter-over-quarter.
- 27 funds opened new Sage Therapeutics positions in Q4 2015 and 23 closed out, a net change of +4 holders.
- The largest Sage Therapeutics buyer in Q4 2015 was Lord, Abbett & Co, an estimated $41.4M added.
- The largest Sage Therapeutics seller in Q4 2015 was T. Rowe Price Associates, an estimated $17.3M sold.
Based on aggregated 13F filings for Q4 2015.